• Molecular NameAliskiren
  • Synonymaliskiren; Rasilez; SPP 100
  • Weight551.769
  • Drugbank_IDDB01258
  • ACS_NO173334-57-1
  • Show 3D model
  • LogP (experiment)2.45
  • LogP (predicted, AB/LogP v2.0)3.44
  • pkaN/A
  • LogD (pH=7, predicted)1.19
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-0.97
  • LogSw (predicted, AB/LogsW2.0)0.05
  • Sw (mg/ml) (predicted, ACD/Labs)0.17
  • No.of HBond Donors6
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds19
  • TPSA146.13
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyThe first in a class of drugs called direct renin inhibitor. Its current licensed indication is primary (previously essential) hypertension.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability2.5
  • Protein binding49.5
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic. About one-fourth of the absorbed dose appears in the urine as parent drug. How much of the absorbed dose is metabolized is unknown. Based on the in vitro studies, the major enzyme responsible for aliskiren metabolism appears to be CYP 3A4
  • Half life24h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most likely manifestation of overdosage would be hypotension.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A